Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) EBT Margin (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of EBT Margin data on record, last reported at 184.87% in Q4 2025.

  • For Q4 2025, EBT Margin rose 48042.0% year-over-year to 184.87%; the TTM value through Dec 2025 reached 291.74%, up 385.0%, while the annual FY2025 figure was 291.74%, 385.0% up from the prior year.
  • EBT Margin reached 184.87% in Q4 2025 per CCCC's latest filing, up from 286.43% in the prior quarter.
  • Across five years, EBT Margin topped out at 77.99% in Q4 2021 and bottomed at 1348.42% in Q2 2023.
  • Average EBT Margin over 5 years is 497.72%, with a median of 327.03% recorded in 2021.
  • Peak YoY movement for EBT Margin: plummeted -120386bps in 2022, then surged 120086bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 77.99% in 2021, then tumbled by -1544bps to 1281.85% in 2022, then increased by 18bps to 1057.25% in 2023, then skyrocketed by 37bps to 665.29% in 2024, then soared by 72bps to 184.87% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 184.87% in Q4 2025, 286.43% in Q3 2025, and 402.6% in Q2 2025.